Determination—Conditions (PB 119 of 2008)
made under paragraph 98C(1)(b) of the
National Health Act 1953
Includes amendments up to: PB 55 of 2019
About this compilation
This compilation
This is a compilation of the Determination—Conditions (PB 119 of 2008) that shows the text of the law as amended and in force on 1 July 2019 (the compilation date).
The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.
Uncommenced amendments
The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.
Application, saving and transitional provisions for provisions and amendments
If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.
Editorial changes
For more information about any editorial changes made in this compilation, see the endnotes.
Modifications
If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.
Self‑repealing provisions
If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.
Determination–Conditions (PB 119 of 2008)
3. “Act” means the National Health Act 1953;
“approved ex‑manufacturer price” has the same meaning as in subsection 84(1) of the Act;
“Commonwealth price” has the same meaning as in subsection 84(1) of the Act;
“extemporaneously‑prepared pharmaceutical benefit” means a pharmaceutical benefit other than a ready‑prepared pharmaceutical benefit;
“pack quantity” has the same meaning as in subsection 84(1) of the Act;
“prescription” includes a prescription written on an authority prescription made under regulation 13 of the Regulations, a prescription required to be submitted to the Chief Executive Medicare for the purposes of a determination made under subsection 85(2A) or subsection 85A(2) of the Act, a repeat authorisation, or a deferred supply authorisation;
“proportional ex‑manufacturer price” has the same meaning as in subsection 84(1) of the Act;
“ready‑prepared pharmaceutical benefit” means a listed brand of a pharmaceutical item;
“Regulations” means the National Health (Pharmaceutical Benefits) Regulations 1960 made under the Act;
“standard formula preparation” means an extemporaneously‑prepared pharmaceutical benefit that is listed in Schedule 5 to this Determination.
4. For the supply of pharmaceutical benefits:
(a) pharmaceutical benefits that involve the admixture of ready‑prepared ingredients are set out in Schedule 1;
(b) drugs that are used in the preparation of extemporaneously‑prepared pharmaceutical benefits and that are unstable or packed sterile and unused quantities of which are unsuitable for future use are set out in Schedule 2;
(c) pharmaceutical benefits that are classified as dangerous drugs for the purpose of payment of a dangerous drug fee are pharmaceutical benefits that have the pharmaceutical items which have the listed drug in the form set out in Schedule 3 to this Determination;
(d) pharmaceutical benefits the complete pack of which shall be supplied regardless of any lesser quantity ordered are pharmaceutical benefits that have the pharmaceutical items which have the listed drug in the form set out in Schedule 4.
5. Where a prescription identifies the ready‑prepared pharmaceutical benefit to be supplied by reference to a particular brand, the amount payable shall be based on the approved ex‑manufacturer price or proportional ex‑manufacturer price for a pack quantity of that brand.
6. Where a prescription does not identify the ready‑prepared pharmaceutical benefit to be supplied by reference to a particular brand, the amount payable shall be based on the approved ex‑manufacturer price or proportional ex‑manufacturer price for a pack quantity of the brand of that benefit, being a brand which is available from a wholesale source in the capital city of the State in which the benefit is supplied, for which the Commonwealth price for the supply of the benefit is lowest.
7. Where a prescription calls for a quantity of one of the pharmaceutical benefits that have the pharmaceutical items which have the form of the listed drug set out in Schedule 4 that is less than the quantity contained in the size of unit included in the particulars specified in the column headed 'Form' in that Schedule in relation to that benefit, the complete pack shall be supplied.
Variation of medicinal preparation
8. A medicinal preparation that is a variation of a standard formula preparation, due to the addition or deletion of an ingredient or to variation of the dose, or that is a combination of standard formula preparations, shall be deemed not to be a standard formula preparation.
Election—extemporaneously‑prepared pharmaceutical benefits
9. An election made pursuant to section 31 of the determination made under paragraph 98B(1)(a) of the Act shall be made in writing to the Chief Executive Medicare and shall remain in force for a period of not less than 3 months from and including the date of election, but may be revoked in writing at any time after the expiration of that period; and while the election remains in force, the amount payable to the approved pharmacist or approved medical practitioner, in respect of the supply of an extemporaneously‑prepared pharmaceutical benefit that is not a standard formula preparation, shall be the amount calculated in accordance with section 18 of the determination made under paragraph 98B(1)(a) of the Act.
SCHEDULE 1—PHARMACEUTICAL BENEFITS THAT INVOLVE THE ADMIXTURE OF READY‑PREPARED INGREDIENTS | |
Listed Drug | Form (strength, type, size, etc.) |
Amoxicillin with Water – Purified BP | Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL |
| Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL |
| Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL |
| Powder for oral suspension 500 mg (as trihydrate) per 5 mL, 100 mL |
Amoxicillin with clavulanic acid and water – purified BP | Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL |
Azithromycin with Water – Purified BP | Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL |
Cefaclor with Water – Purified BP | Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL |
Cefalexin with water – purified BP | Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL |
Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL Powder for oral suspension 125 mg (as axetil) per 5 mL, 100 mL | |
Clarithromycin with Water – Purified BP | Powder for oral liquid 250 mg per 5 mL, 50 mL |
Erythromycin with Water – Purified BP | Powder for oral liquid 200 mg (as ethyl succinate) per 5 mL, 100 mL Powder for oral liquid 400 mg (as ethyl succinate) per 5 mL, 100 mL |
Flucloxacillin with Water – Purified BP | Powder for oral liquid 125 mg (as sodium monohydrate) per 5 mL, 100 mL Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL |
Fluconazole with Water – Purified BP | Powder for oral suspension 50 mg in 5 mL, 35 mL |
Mycophenolic Acid with Water – Purified BP | Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL |
Phenoxymethylpenicillin with Water – Purified BP | Powder for oral liquid 125 mg (as potassium) per 5 mL, 100 mL Powder for oral liquid 250 mg (as potassium) per 5 mL, 100 mL |
Valganciclovir with water — purified BP | Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL |
Voriconazole with Water—Purified BP | Powder for oral suspension 40 mg per mL, 70 mL |
SCHEDULE 2—DRUGS THAT ARE USED IN THE PREPARATION OF EXTEMPORANEOUSLY‑PREPARED PHARMACEUTICAL BENEFITS AND THAT ARE UNSTABLE OR PACKED STERILE AND UNUSED QUANTITIES OF WHICH ARE UNSUITABLE FOR FUTURE USE | |
Listed Drug | Form (strength, type, size, etc.) |
Water For Injections—sterilised BP |
SCHEDULE 3—PHARMACEUTICAL BENEFITS THAT ARE CLASSIFIED AS DANGEROUS DRUGS FOR THE PURPOSE OF PAYMENT OF A DANGEROUS DRUG FEE | |
Listed Drug | Form (strength, type, size, etc.) |
Alprazolam | Tablet 250 micrograms |
| Tablet 500 micrograms |
| Tablet 1 mg |
Buprenorphine | Transdermal patch 5 mg |
| Transdermal patch 10 mg |
| Transdermal patch 15 mg |
| Transdermal patch 20 mg |
| Transdermal patch 25 mg |
| Transdermal patch 30 mg |
| Transdermal patch 40 mg |
Codeine | Tablet containing codeine phosphate hemihydrate 30 mg |
Dexamfetamine | Tablet containing dexamfetamine sulfate 5 mg |
Fentanyl | Lozenge 200 micrograms (as citrate) |
| Lozenge 400 micrograms (as citrate) |
| Lozenge 600 micrograms (as citrate) |
| Lozenge 800 micrograms (as citrate) |
| Lozenge 1200 micrograms (as citrate) |
| Lozenge 1600 micrograms (as citrate) |
| Tablet (orally disintegrating) 100 micrograms (as citrate) |
| Tablet (orally disintegrating) 200 micrograms (as citrate) |
| Tablet (orally disintegrating) 400 micrograms (as citrate) |
| Tablet (orally disintegrating) 600 micrograms (as citrate) |
| Tablet (orally disintegrating) 800 micrograms (as citrate) |
| Tablet (sublingual) 100 micrograms (as citrate) |
| Tablet (sublingual) 200 micrograms (as citrate) |
| Tablet (sublingual) 300 micrograms (as citrate) |
| Tablet (sublingual) 400 micrograms (as citrate) |
| Tablet (sublingual) 600 micrograms (as citrate) |
| Tablet (sublingual) 800 micrograms (as citrate) |
| Transdermal patch 1.28 mg |
| Transdermal patch 2.063 mg |
| Transdermal patch 2.1 mg |
| Transdermal patch 2.55 mg |
| Transdermal patch 4.125 mg |
| Transdermal patch 4.2 mg |
| Transdermal patch 5.10 mg |
| Transdermal patch 7.65 mg |
| Transdermal patch 8.25 mg |
| Transdermal patch 8.4 mg |
| Transdermal patch 10.20 mg |
| Transdermal patch 12.375 mg |
| Transdermal patch 12.6 mg |
| Transdermal patch 16.5 mg |
| Transdermal patch 16.8 mg |
Hydromorphone | Tablet containing hydromorphone hydrochloride 2 mg |
| Tablet containing hydromorphone hydrochloride 4 mg |
| Tablet containing hydromorphone hydrochloride 8 mg |
| Tablet (modified release) containing hydromorphone hydrochloride 4 mg |
| Tablet (modified release) containing hydromorphone hydrochloride 8 mg |
| Tablet (modified release) containing hydromorphone hydrochloride 16 mg |
| Tablet (modified release) containing hydromorphone hydrochloride 32 mg |
| Tablet (modified release) containing hydromorphone hydrochloride 64 mg |
| Oral liquid containing hydromorphone hydrochloride 1 mg per mL, 200 mL |
| Injection containing hydromorphone hydrochloride 2 mg in 1 mL |
| Injection containing hydromorphone hydrochloride 10 mg in 1 mL |
Lisdexamfetamine | Capsule containing lisdexamfetamine dimesilate 30 mg |
| Capsule containing lisdexamfetamine dimesilate 50 mg |
| Capsule containing lisdexamfetamine dimesilate 70 mg |
Methadone | Tablet containing methadone hydrochloride 10 mg |
| Oral liquid containing methadone hydrochloride 25 mg per 5 mL, 200 mL |
| Injection containing methadone hydrochloride 10 mg in 1 mL |
Methylphenidate | Tablet containing methylphenidate hydrochloride 10 mg |
| Tablet containing methylphenidate hydrochloride 18 mg (extended release) |
| Tablet containing methylphenidate hydrochloride 27 mg (extended release) |
| Tablet containing methylphenidate hydrochloride 36 mg (extended release) |
| Tablet containing methylphenidate hydrochloride 54 mg (extended release) |
| Capsule containing methylphenidate hydrochloride 10 mg (modified release) |
| Capsule containing methylphenidate hydrochloride 20 mg (modified release) |
| Capsule containing methylphenidate hydrochloride 30 mg (modified release) |
| Capsule containing methylphenidate hydrochloride 40 mg (modified release) |
Morphine | Capsule containing morphine sulfate pentahydrate 10 mg (containing sustained release pellets) |
| Capsule containing morphine sulfate pentahydrate 20 mg (containing sustained release pellets) |
| Capsule containing morphine sulfate pentahydrate 50 mg (containing sustained release pellets) |
| Capsule containing morphine sulfate pentahydrate 100 mg (containing sustained release pellets) |
| Capsule containing morphine sulfate pentahydrate 30 mg (controlled release) |
| Capsule containing morphine sulfate pentahydrate 60 mg (controlled release) |
| Capsule containing morphine sulfate pentahydrate 90 mg (controlled release) |
| Capsule containing morphine sulfate pentahydrate 120 mg (controlled release) |
| Injection containing morphine hydrochloride trihydrate 10 mg in 1 mL |
| Injection containing morphine hydrochloride trihydrate 20 mg in 1 mL |
| Injection containing morphine hydrochloride trihydrate 50 mg in 5 mL |
| Injection containing morphine hydrochloride trihydrate 100 mg in 5 mL |
| Injection containing morphine sulfate pentahydrate 10 mg in 1 mL |
| Injection containing morphine sulfate pentahydrate 15 mg in 1 mL |
| Injection containing morphine sulfate pentahydrate 30 mg in 1 mL |
| Injection containing morphine tartrate 120 mg in 1.5 mL |
| Oral solution containing morphine hydrochloride trihydrate 2 mg per mL, 200 mL |
| Oral solution containing morphine hydrochloride trihydrate 5 mg per mL, 200 mL |
| Oral solution containing morphine hydrochloride trihydrate 10 mg per mL, 200 mL |
| Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 20 mg per sachet |
| Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 30 mg per sachet |
| Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 60 mg per sachet |
| Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 100 mg per sachet |
| Sachet containing controlled release granules for oral suspension, containing morphine sulfate pentahydrate 200 mg per sachet |
| Tablet containing morphine sulfate pentahydrate 10 mg |
| Tablet containing morphine sulfate pentahydrate 20 mg |
| Tablet containing morphine sulfate pentahydrate 30 mg |
| Tablet containing morphine sulfate pentahydrate 5 mg (controlled release) |
| Tablet containing morphine sulfate pentahydrate 10 mg (controlled release) |
| Tablet containing morphine sulfate pentahydrate 15 mg (controlled release) |
| Tablet containing morphine sulfate pentahydrate 30 mg (controlled release) |
| Tablet containing morphine sulfate pentahydrate 60 mg (controlled release) |
| Tablet containing morphine sulfate pentahydrate 100 mg (controlled release) |
| Tablet containing morphine sulfate pentahydrate 200 mg (controlled release) |
Oxycodone | Tablet containing oxycodone hydrochloride 5 mg |
| Capsule containing oxycodone hydrochloride 5 mg |
| Capsule containing oxycodone hydrochloride 10 mg |
| Capsule containing oxycodone hydrochloride 20 mg |
| Oral solution containing oxycodone hydrochloride 1 mg per mL, 250 mL |
| Tablet containing oxycodone hydrochloride 10 mg (controlled release) |
| Tablet containing oxycodone hydrochloride 15 mg (controlled release) |
| Tablet containing oxycodone hydrochloride 20 mg (controlled release) |
| Tablet containing oxycodone hydrochloride 30 mg (controlled release) |
| Tablet containing oxycodone hydrochloride 40 mg (controlled release) |
| Tablet containing oxycodone hydrochloride 80 mg (controlled release) |
| Suppository 30 mg (as pectinate) |
Oxycodone with naloxone | Tablet (controlled release) containing oxycodone hydrochloride 2.5 mg with naloxone hydrochloride 1.25 mg |
| Tablet (controlled release) containing oxycodone hydrochloride 5 mg with naloxone hydrochloride 2.5 mg |
| Tablet (controlled release) containing oxycodone hydrochloride 10 mg with naloxone hydrochloride 5 mg |
| Tablet (controlled release) containing oxycodone hydrochloride 15 mg with naloxone hydrochloride 7.5 mg |
| Tablet (controlled release) containing oxycodone hydrochloride 20 mg with naloxone hydrochloride 10 mg |
| Tablet (controlled release) containing oxycodone hydrochloride 30 mg with naloxone hydrochloride 15 mg |
| Tablet (controlled release) containing oxycodone hydrochloride 40 mg with naloxone hydrochloride 20 mg |
| Tablet (controlled release) containing oxycodone hydrochloride 60 mg with naloxone hydrochloride 30 mg |
| Tablet (controlled release) containing oxycodone hydrochloride 80 mg with naloxone hydrochloride 40 mg |
Tapentadol | Tablet (modified release) 50 mg (as hydrochloride) |
| Tablet (modified release) 100 mg (as hydrochloride) |
| Tablet (modified release) 150 mg (as hydrochloride) |
| Tablet (modified release) 200 mg (as hydrochloride) |
| Tablet (modified release) 250 mg (as hydrochloride) |
SCHEDULE 5—LIST OF STANDARD FORMULA PREPARATIONS | ||
Form of pharmaceutical benefit | Standard formula preparations | |
Creams | Salicylic Acid and Sulfur Aqueous APF | |
Dusting Powders | Zinc, Starch and Talc APF 15 Zinc, Starch and Talc BPC 1973 | |
Ear Drops | Aluminium Acetate APF | |
| Aluminium Acetate BP | |
| Sodium Bicarbonate APF | |
| Sodium Bicarbonate BP | |
| Spirit APF | |
Eye Drops containing Cocaine Hydrochloride BP | — | |
Eye Drops, Other | — | |
Eye Lotions | — | |
Inhalations | Benzoin and Menthol APF Menthol APF Menthol and Eucalyptus BP 1980 | |
Linctuses containing Codeine Phosphate | Codeine APF | |
Linctuses, Other | — | |
Lotions | Aluminium Acetate Aqueous APF | |
Mixtures containing Codeine Phosphate | — | |
Mixtures, Other | Gentian Alkaline APF | |
| Kaolin BPC 1968 | |
| Kaolin and Opium APF 14 | |
| Magnesium Trisilicate BPC 1968 | |
| Magnesium Trisilicate and Belladonna BPC 1968 | |
Mixtures for Children containing Codeine Phosphate BP | — | |
Mixtures for Children, Other | — | |
Mouth Washes | Thymol Compound APF 15 | |
Nasal Instillations | — | |
Ointments, Waxes | Benzoic Acid Compound APF | |
| Benzoic Acid Compound (extemporaneous formula) BP | |
| Boric Acid, Olive Oil and Zinc Oxide QHF | |
| Salicylic Acid APF | |
| Salicylic Acid (extemporaneous formula) BP | |
Paints | Podophyllin Compound APF 16 Podophyllin Compound BP Salicylic Acid APF | |
Pastes containing Cocaine Hydrochloride | — | |
Pastes, Other | Zinc APF Zinc Compound (extemporaneous formula) BP | |
Powders for Internal Use | Magnesium Trisilicate BP | |
Solutions | — | |
The endnotes provide information about this compilation and the compiled law.
The following endnotes are included in every compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.
Editorial changes
The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.
If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.
Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.
If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.
ad = added or inserted | o = order(s) |
am = amended | Ord = Ordinance |
amdt = amendment | orig = original |
c = clause(s) | par = paragraph(s)/subparagraph(s) |
C[x] = Compilation No. x | |
Ch = Chapter(s) | pres = present |
def = definition(s) | prev = previous |
Dict = Dictionary | (prev…) = previously |
disallowed = disallowed by Parliament | Pt = Part(s) |
Div = Division(s) | r = regulation(s)/rule(s) |
ed = editorial change | reloc = relocated |
exp = expires/expired or ceases/ceased to have | renum = renumbered |
rep = repealed | |
F = Federal Register of Legislation | rs = repealed and substituted |
gaz = gazette | s = section(s)/subsection(s) |
Sch = Schedule(s) | |
Sdiv = Subdivision(s) | |
(md) = misdescribed amendment can be given | SLI = Select Legislative Instrument |
SR = Statutory Rules | |
(md not incorp) = misdescribed amendment | Sub‑Ch = Sub‑Chapter(s) |
SubPt = Subpart(s) | |
mod = modified/modification | underlining = whole or part not |
No. = Number(s) |
Name | Registration | Commencement | Application, saving and transitional provisions |
PB 119 of 2008 | 28 Nov 2008 (F2008L02618) | 1 Dec 2008 |
|
PB 131 of 2008 | 11 Dec 2008 (F2008L04645) | 1 Jan 2009 | — |
PB 26 of 2009 | 18 Mar 2009 (F2009L01117) | 1 Apr 2009 | — |
PB 38 of 2009 | 15 Apr 2009 (F2009L01321) | 1 May 2009 | — |
PB 42 of 2009 | 11 May 2009 (F2009L01714) | 1 June 2009 | — |
PB 53 of 2009 | 11 June 2009 (F2009L02293) | 1 July 2009 | — |
PB 68 of 2009 | 10 July 2009 (F2009L02717) | 1 Aug 2009 | — |
PB 81 of 2009 | 17 Aug 2009 (F2009L03153) | 1 Sept 2009 | — |
PB 112 of 2009 | 20 Nov 2009 (F2009L04263) | 1 Dec 2009 | — |
PB 122 of 2009 | 10 Dec 2009 (F2009L04556) | 1 Jan 2010 | — |
PB 131 of 2009 | 13 Jan 2010 (F2010L00104) | 1 Feb 2010 | — |
PB 20 of 2010 | 17 Mar 2010 (F2010L00678) | 1 Apr 2010 | — |
as amended by |
|
|
|
PB 32 of 2010 | 30 Mar 2010 (F2010L00775) | 31 Mar 2010 | — |
PB 39 of 2010 | 15 Apr 2010 (F2010L00941) | 1 May 2010 | — |
PB 48 of 2010 | 21 May 2010 (F2010L01379) | 1 June 2010 | — |
PB 58 of 2010 | 21 June 2010 (F2010L01622) | 1 July 2010 | — |
PB 73 of 2010 | 19 July 2010 (F2010L02067) | 1 Aug 2010 | — |
PB 99 of 2010 | 29 Oct 2010 (F2010L02858) | 1 Nov 2010 | — |
30 Nov 2010 (F2010L03128) | 1 Dec 2010 | — | |
PB 121 of 2010 | 17 Dec 2010 (F2010L03306) | 1 Jan 2011 | — |
PB 8 of 2011 | 28 Jan 2011 (F2011L00164) | 1 Feb 2011 | — |
PB 26 of 2011 | 28 Mar 2011 (F2011L00509) | 1 Apr 2011 | — |
PB 37 of 2011 | 26 May 2011 (F2011L00867) | 1 June 2011 | — |
PB 52 of 2011 | 27 July 2011 (F2011L01544) | 1 Aug 2011 | — |
PB 59 of 2011 | 29 Aug 2011 (F2011L01764) | 1 Sept 2011 | — |
PB 68 of 2011 | 28 Sept 2011 (F2011L01986) | 1 Oct 2011 | — |
PB 85 of 2011 | 28 Nov 2011 (F2011L02475) | 1 Dec 2011 | — |
PB 97 of 2011 | 19 Dec 2011 (F2011L02736) | 1 Jan 2012 | — |
PB 15 of 2012 | 29 Mar 2012 (F2011L00715) | 1 Apr 2012 | — |
PB 29 of 2012 | 26 Apr 2012 (F2012L00937) | 1 May 2012 | — |
PB 34 of 2012 | 8 May 2012 (F2012L01004) | 1 June 2012 | — |
PB 38 of 2012 | 15 June 2012 (F2012L01202) | 1 July 2012 | — |
PB 46 of 2012 | 25 July 2012 (F2012L01601) | 1 Aug 2012 | — |
PB 63 of 2012 | 22 Aug 2012 (F2012L01732) | 1 Sept 2012 | — |
PB 75 of 2012 | 28 Sept 2012 (F2012L01969) | 1 Oct 2012 | — |
PB 95 of 2012 | 29 Nov 2012 (F2012L02287) | 1 Dec 2012 | — |
PB 5 of 2013 | 21 Jan 2013 (F2013L00071) | 22 Jan 2013 (s 2) | — |
PB 9 of 2013 | 14 Feb 2013 (F2013L00186) | 1 Mar 2013 (s 2) | — |
PB 33 of 2013 | 24 May 2013 (F2013L00840) | 1 June 2013 (s 2) | — |
PB 49 of 2013 | 29 July 2013 (F2013L01459 | 1 Aug 2013 (s 2) | — |
15 Aug 2013 (F2013L01578) | 1 Sept 2013 (s 2) | — | |
PB 80 of 2013 | 29 Nov 2013 (F2013L02015) | 1 Dec 2013 (s 2) | — |
PB 91 of 2013 | 20 Dec 2013 (F2013L02167) | 1 Jan 2014 (s 2) | — |
PB 3 of 2014 | 10 Jan 2014 (F2014L00050) | 1 Feb 2014 (s 2) | — |
PB 10 of 2014 | 14 Feb 2014 (F2014L00144) | 1 Mar 2014 (s 2) | — |
PB 19 of 2014 | 27 Mar 2014 (F2014L00357) | 1 Apr 2014 (s 2) | — |
PB 29 of 2014 | 11 Apr 2014 (F2014L00401) | 1 May 2014 (s 2) | — |
PB 38 of 2014 | 22 May 2014 (F2014L00593) | 1 June 2014 (s 2) | — |
PB 46 of 2014 | 19 June 2014 (F2014L00761) | 1 July 2014 (s 2) | — |
PB 57 of 2014 | 30 July 2014 (F2014L01052 ) | 1 Aug 2014 (s 2) | — |
PB 62 of 2014 | 25 Aug 2014 (F2014L01125) | 1 Sept 2014 (s 2) | — |
PB 74 of 2014 | 26 Sept 2014 (F2014L01256) | 1 Oct 2014 (s 2) | — |
PB 83 of 2014 | 23 Oct 2014 (F2014L01393) | 1 Nov 2014 (s 2) | — |
PB 90 of 2014 | 28 Nov 2014 (F2014L01599) | 1 Dec 2014 (s 2) | — |
PB 108 of 2014 | 22 Dec 2014 (F2014L01772) | 1 Jan 2015 (s 2) | — |
PB 2 of 2015 | 14 Jan 2015 (F2015L00039) | 1 Feb 2015 (s 2) | — |
PB 12 of 2015 | 25 Feb 2015 (F2015L00207) | 1 Mar 2015 (s 2) | — |
PB 28 of 2015 | 26 Mar 2015 (F2015L00338) | 1 Apr 2015 (s 2) | — |
PB 41 of 2015 | 24 Apr 2015 (F2015L00589) | 1 May 2015 (s 2) | — |
PB 49 of 2015 | 29 May 2015 (F2015L00764) | 1 June 2015 (s 2) | — |
PB 56 of 2015 | 1 July 2015 (F2015L01065) | 1 July 2015 (s 2) | — |
PB 70 of 2015 | 31 July 2015 (F2015L01205) | 1 Aug 2015 (s 2) | — |
PB 80 of 2015 | 28 Aug 2015 (F2015L01350) | 1 Sept 2015 (s 2) | — |
PB 92 of 2015 | 30 Sept 2015 (F2015L01539) | 1 Oct 2015 (s 2) | — |
PB 109 of 2015 | 1 Dec 2015 (F2015L01894) | 1 Dec 2015 (s 2) | — |
PB 119 of 2015 | 24 Dec 2015 (F2015L02139) | 1 Jan 2016 (s 2) | — |
PB 3 of 2016 | 1 Feb 2016 (F2016L00077) | 1 Feb 2016 (s 2) | — |
PB 20 of 2016 | 1 Apr 2016 (F2016L00469) | 1 Apr 2016 (s 2) | — |
PB 31 of 2016 | 29 Apr 2016 (F2016L00603) | 1 May 2016 (s 2) | — |
PB 44 of 2016 | 30 May 2016 (F2016L00855) | 1 June 2016 (s 2) | — |
PB 53 of 2016 | 22 June 2016 (F2016L01058) | 1 July 2016 (s 2) | — |
PB 65 of 2016 | 19 July 2016 (F2016L01196) | 1 Aug 2016 (s 2) | — |
PB 74 of 2016 | 18 Aug 2016 (F2016L01298) | 1 Sept 2016 (s 2) | — |
PB 108 of 2016 | 30 Nov 2016 (F2016L01835) | 1 Dec 2016 (s 2) | — |
PB 3 of 2017 | 25 Jan 2017 (F2017L00071) | 1 Feb 2017 (s 2) | — |
PB 18 of 2017 | 30 Mar 2017 (F2017L00355) | 1 Apr 2017 (s 2) | — |
PB 28 of 2017 | 28 Apr 2017 (F2017L00488) | 1 May 2017 (s 2) | — |
PB 36 of 2017 | 31 May 2017 (F2017L00620) | 1 June 2017 (s 2) | — |
PB 64 of 2017 | 30 Aug 2017 (F2017L01109) | 1 Sept 2017 (s 2) | — |
PB 73 of 2017 | 27 Sept 2017 (F2017L01277) | 1 Oct 2017 (s 2) | — |
PB 86 of 2017 | 24 Oct 2017 (F2017L01386) | 1 Nov 2017 (s 2) | — |
PB 110 of 2017 | 18 Dec 2017 (F2017L01628) | 1 Jan 2018 (s 2) | — |
PB 3 of 2018 | 24 Jan 2018 (F2018L00059) | 1 Feb 2018 (s 2) | — |
PB 13 of 2018 | 28 Feb 2018 (F2018L00163) | 1 Mar 2018 (s 2) | — |
PB 31 of 2018 | 1 May 2018 (F2018L00547) | 1 May 2018 (s 2) | — |
PB 38 of 2018 | 31 May 2018 (F2018L00690) | 1 June 2018 (s 2) | — |
PB 64 of 2018 | 1 Aug 2018 (F2018L01076) | 1 Aug 2018 (s 2) | — |
PB 84 of 2018 | 27 Sept 2018 (F2018L01348) | 1 Oct 2018 (s 2) | — |
PB 92 of 2018 | 29 Oct 2018 (F2018L01485) | 1 Nov 2018 (s 2) | — |
PB 11 of 2019 | 27 Feb 2019 (F2019L00212) | 1 Mar 2019 (s 2) | — |
PB 18 of 2019 | 28 Mar 2019 (F2019L00448) | 1 Apr 2019 (s 2) | — |
PB 29 of 2019 | 30 Apr 2019 (F2019L00660) | 1 May 2019 (s 2) | — |
PB 37 of 2019 | 30 May 2019 (F2019L00708) | 1 June 2019 (s 2) | — |
PB 55 of 2019 | 28 June 2019 (F2019L00904) | 1 July 2019 (s 2) | — |